Skip to main content
Top
Published in: The European Journal of Health Economics 6/2011

01-12-2011 | Editorial

Budget impact analysis in economic evaluation: a proposal for a clearer definition

Authors: Livio Garattini, Katelijne van de Vooren

Published in: The European Journal of Health Economics | Issue 6/2011

Login to get access

Excerpt

Budget impact analysis (BIA) is a relatively recent method for economic evaluation (EE) in the field of health care. It assesses the financial consequences of the introduction of a new technology in a specific setting in the short-to-medium term [1]. BIA is supposed to be complementary to more established types of EEs, providing additional information for decisions on the reimbursement of new technology [1]. …
Literature
1.
go back to reference Trueman, P., Drummond, M., Hutton, J.: Developing guidance for budget impact analysis. Pharmacoeconomics 19, 609–621 (2001)PubMedCrossRef Trueman, P., Drummond, M., Hutton, J.: Developing guidance for budget impact analysis. Pharmacoeconomics 19, 609–621 (2001)PubMedCrossRef
2.
go back to reference Mauskopf, J.A., Sullivan, S.D., Annemans, L., et al.: Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices-budget impact analysis. Value Health 10, 336–347 (2007)PubMedCrossRef Mauskopf, J.A., Sullivan, S.D., Annemans, L., et al.: Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices-budget impact analysis. Value Health 10, 336–347 (2007)PubMedCrossRef
3.
go back to reference Marshall, D.A., Douglas, P.R., Drummond, M.F., et al.: Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics 26, 477–495 (2008)PubMedCrossRef Marshall, D.A., Douglas, P.R., Drummond, M.F., et al.: Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics 26, 477–495 (2008)PubMedCrossRef
4.
go back to reference Orlewska, E., Gulácsi, L.: Budget-impact analyses, a critical review of published studies. Pharmacoeconomics 27, 807–827 (2009)PubMedCrossRef Orlewska, E., Gulácsi, L.: Budget-impact analyses, a critical review of published studies. Pharmacoeconomics 27, 807–827 (2009)PubMedCrossRef
5.
go back to reference Weinstein, M., Siegel, J., Gold, M., Kamlet, M., et al.: Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276, 1253–1258 (1996)PubMedCrossRef Weinstein, M., Siegel, J., Gold, M., Kamlet, M., et al.: Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276, 1253–1258 (1996)PubMedCrossRef
6.
go back to reference Drummond, M., O’Brien, B., Stoddart, G., Torrance, G.: Methods for the economic evaluation of health care programmes, 2nd edn. Oxford Medical Publications, Oxford (1997) Drummond, M., O’Brien, B., Stoddart, G., Torrance, G.: Methods for the economic evaluation of health care programmes, 2nd edn. Oxford Medical Publications, Oxford (1997)
7.
go back to reference Orlewska, E., Mierzejewski, P.: Proposal of polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 7, 1–10 (2004)PubMedCrossRef Orlewska, E., Mierzejewski, P.: Proposal of polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 7, 1–10 (2004)PubMedCrossRef
8.
go back to reference Nuijten, M., Mittendorf, T., Persson, U.: Practical issues in handling data input and uncertainty in a budget impact analysis. Eur. J. Health Econ. 12, 231–241 (2011)PubMedCrossRef Nuijten, M., Mittendorf, T., Persson, U.: Practical issues in handling data input and uncertainty in a budget impact analysis. Eur. J. Health Econ. 12, 231–241 (2011)PubMedCrossRef
9.
go back to reference Garattini, L., Grilli, R., Scopelliti, D., Mantovani, L.: A proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics 7, 1–6 (1995)PubMedCrossRef Garattini, L., Grilli, R., Scopelliti, D., Mantovani, L.: A proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics 7, 1–6 (1995)PubMedCrossRef
10.
go back to reference Drummond, M., Dubois, D., Garattini, L., Horisberger, B., et al.: Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value Health 2, 323–332 (1999) Drummond, M., Dubois, D., Garattini, L., Horisberger, B., et al.: Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value Health 2, 323–332 (1999)
11.
go back to reference Hutter, F., Antoñanzas, F.: Economic evaluations in the EURONHEED: a comparative analysis. Pharmacoeconomics 27, 561–570 (2009) Hutter, F., Antoñanzas, F.: Economic evaluations in the EURONHEED: a comparative analysis. Pharmacoeconomics 27, 561–570 (2009)
Metadata
Title
Budget impact analysis in economic evaluation: a proposal for a clearer definition
Authors
Livio Garattini
Katelijne van de Vooren
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 6/2011
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-011-0348-5

Other articles of this Issue 6/2011

The European Journal of Health Economics 6/2011 Go to the issue